BibTex RIS Cite

Oksaliplatin-Temelli Rejim Altında Progresyon Gösteren Metastatik Kolorektal Kanserli Hastalarda Modifiye Folfiri-Bevasizumab Rejimi

Year 2017, Yıl: 2017 Sayı: 1, 53 - 59, 01.03.2017

Doğan Koca Davut Demir Oğuzhan Özdemir Hüseyin Akdeniz Mehmet Kurt

Abstract

İlk-sıra tedavide oksaliplatin-temelli rejim alan metastatik kolorektal kanserli (mKRK) hastalarda ikinci-sıra tedavide modifiye FOLFIRI-Bevacizumab (mFOLFIRI-B) rejiminin etkinlik ve tolerabilitesi araştırıldı. Materyal ve Metot: Çalışmaya ilk-sıra tedavide oksaliplatin-temelli rejim alan, ardından progresyon gözlenen ve ikinci-sıra tedavide mFOLFIRI-B rejimi alan mKRK’li hastalar alındı. Toksisite ve etkinlik ile ilgili veriler retrospektif olarak değerlendirildi.Bulgular: Toplam 172 mKRK’li hasta ikinci-sıra tedavide mFOLFIRI-B rejimi almıştı. Hastaların %39,5’inde objektif cevap, 9,0 aylık (7,6 ile 10,3 arası) median progresyonsuz yaşam, 19,0 aylık (15,1 ile 26,2 arası) median tüm yaşam saptandı. Grade 3/4 toksisite %33,7 oranında tespit edildi. Grade 3/4 hematolojik toksisite %31,9 oranında tespit edildi. Sonuç: Sonuç olarak mKRK’li hastalarda oksaliplatin-temelli rejim sonrası ikinci-sıra tedavide mFOLFIRI-B rejimi etkili ve güvenilir bir tedavi rejimidir.

Keywords

metastatik kolorektal kanser ikinci-sıra kemoterapi rejimi modifiye FOLFIRI-Bevacizumab rejimi

Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen

Year 2017, Yıl: 2017 Sayı: 1, 53 - 59, 01.03.2017

Doğan Koca Davut Demir Oğuzhan Özdemir Hüseyin Akdeniz Mehmet Kurt

Abstract

We aimed to investigate the efficacy and tolerability of modified FOLFIRI-Bevacizumab (mFOLFIRI-B) regime in the secondline treatment of metastatic colorectal cancer (mCRC) patients who received oxaliplatin-based regimen in the first-line treatment. Material and Method: The patients treated with mFOLFIRI-B regimen in second-line therapy who had progressed after oxaliplatin- based chemotherapy were included in this study. The datas of toxicity and efficacy of the regimen were retrospectively evaluated. Results: Total 172 mCRC patients had received mFOLFIRI-B regime in the second-line treatment. 39.5% objective response rate, 9.0 months (7.6 to 10.3) median progression-free survival, 19.0 months (15.1 to 26.2) median overall survival were found. Grade 3/4 toxicity was observed in 33.7%. Grade 3/4 hematologic toxicity was most frequently observed toxicity (31.9%). Conclusion: mFOLFIRI-B is an efficient and safe regimen for the second-line treatment of mCRC patients after the oxaliplatinbased regimen.

Keywords

metastatic colorectal cancer second-line chemotherapy modified FOLFIRI-Bevacizumab

There are 0 citations in total.

Details

Other ID JA79EN39HF
Journal Section Research Article
Authors

Doğan Koca This is me

Davut Demir This is me

Oğuzhan Özdemir This is me

Hüseyin Akdeniz This is me

Mehmet Kurt This is me

Publication Date March 1, 2017
Published in Issue Year 2017 Yıl: 2017 Sayı: 1

Cite

APA Koca, D., Demir, D., Özdemir, O., Akdeniz, H., et al. (2017). Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. Kafkas Journal of Medical Sciences, 7(1), 53-59.
AMA Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. KAFKAS TIP BİL DERG. April 2017;7(1):53-59.
Chicago Koca, Doğan, Davut Demir, Oğuzhan Özdemir, Hüseyin Akdeniz, and Mehmet Kurt. “Modified FOLFIRI-Bevacizumab Regimen in the Patients With Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”. Kafkas Journal of Medical Sciences 7, no. 1 (April 2017): 53-59.
EndNote Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M (April 1, 2017) Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. Kafkas Journal of Medical Sciences 7 1 53–59.
IEEE D. Koca, D. Demir, O. Özdemir, H. Akdeniz, and M. Kurt, “Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”, KAFKAS TIP BİL DERG, vol. 7, no. 1, pp. 53–59, 2017.
ISNAD Koca, Doğan et al. “Modified FOLFIRI-Bevacizumab Regimen in the Patients With Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”. Kafkas Journal of Medical Sciences 7/1 (April 2017), 53-59.
JAMA Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. KAFKAS TIP BİL DERG. 2017;7:53–59.
MLA Koca, Doğan et al. “Modified FOLFIRI-Bevacizumab Regimen in the Patients With Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”. Kafkas Journal of Medical Sciences, vol. 7, no. 1, 2017, pp. 53-59.
Vancouver Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. KAFKAS TIP BİL DERG. 2017;7(1):53-9.